AMRN — Q2 2026 Financial Report Analysis

Revenue fell 42% because a one-off payment didn't repeat; the bigger problem is the price Amarin now gets per capsule

Amarin sells one drug: VASCEPA (icosapent ethyl, a purified fish-oil prescription that lowers cardiovascular risk in some statin patients). Generic copies have been on sale in the US since 2020. In the second quarter of 2026, total revenue fell to $42.2 million from $72.7 million. Most of that drop is a single item: in Q2 2025 Amarin booked a $25.0 million upfront payment from Recordati when it handed its European business to that partner, and nothing like it recurred this year.

Strip that out and the picture splits in two. Costs are far lower: operating expenses excluding restructuring fell 38%, to $27.0 million, after the 2025 job cuts. But the core product is earning much less per unit. Amarin shipped more capsules (cost of goods sold rose 22% "due to increased product volumes") while product revenue fell 16%. The gross margin on product sales, meaning the share of sales left after paying to make and ship the capsules, dropped from 52% to 30%. The company says this was "a change in customer mix": it is selling more to buyers who pay a lower net price.

The net loss narrowed to $7.7 million ($0.37 per ADS) from $14.1 million ($0.68 per ADS). Amarin's US-traded shares are American Depositary Shares, and one ADS equals 20 ordinary shares since an April 2025 ratio change.

At a glance

• Product gross margin 30%, down from 52%. Amarin moved more volume but earned far less on each sale, and the margin also fell from about 37% in Q1 2026. That is the number to watch.
• Operating expenses (excluding restructuring) down $16.6 million, or 38%. The 2025 restructuring is done and the savings are showing up in the results. This is why the loss shrank even though revenue fell.
• $314.6 million in cash and short-term investments, no debt. That is up $12.0 million since December. Management expects about 10% growth over the full year. Most of this year's cash inflow came from running down inventory and collecting receivables, not from profits.

Key figures

Operating margin is operating loss divided by total revenue. "IPE market" means all US prescriptions of icosapent ethyl, both branded VASCEPA and generic.

Where the revenue went

• United States ($32.2M, -12%). The 10-Q says the decline was "primarily due to a lower net selling price associated with changes in customer mix." Demand for the brand rose. The total US icosapent ethyl market grew 3%, VASCEPA's share rose to about 48% from 43%, and branded prescriptions were up 17% according to the 10-Q (the earnings release says 14%, and the filing does not explain the gap). So Amarin is winning back prescriptions from generics, but it is doing so at a lower net price.
• Europe ($5.4M, -18%). Since mid-2025, Recordati sells the drug in Europe (where it is branded VAZKEPA) and Amarin sells capsules to Recordati at a supply price. The filing notes that its margin is "higher where we sell VASCEPA directly," so less revenue per capsule is built into this arrangement. The company says like-for-like European comparisons only begin in Q3 2026. Recordati's in-market demand rose 69% year over year, per the release.
• Rest of world ($1.4M, -60%). This covers partners in Canada, China, Australia, the Middle East, Southeast Asia and Israel. Management calls the drop "normal variability" in when partners place orders. The release says partners' in-market demand rose 59% across the network.
• Licensing and royalties ($3.1M vs $26.1M). Last year's figure included the $25.0M Recordati upfront payment. This year it is ongoing royalties only, which the filing says are now higher because partner sales grew.

What the headline numbers hide

• The cost savings are real, but the product margin decline is eating them. Excluding the $25.0M upfront payment and the $22.8M restructuring charge, Q2 2025's operating loss would have been about $18.2M. Q2 2026's $12.0M loss includes $6.3M of litigation-related charges, and without them it would have been about $5.7M. So the underlying business improved by roughly $12–13M per quarter, but only because opex fell faster than gross profit. Product gross profit (product revenue minus all cost of goods) fell to about $11.9M from $24.2M. Selling expense has already dropped 81% to $2.8M, so there is little room left to cut.
• The margin decline is getting worse. Using the six-month and quarterly figures, product gross margin was about 37% in Q1 2026 and 30% in Q2. For the half year it was 34%, compared with 55% a year earlier. The filing does not say which customers pay the lower price or whether the mix shift will reverse.
• Cash flow is better than earnings, but mostly because of working capital. Operating cash flow for the first half was +$13.0M against a net loss of $18.2M. Collecting receivables added $33.9M and drawing down inventory added $31.8M (inventory is now $164.1M, down from $195.9M in December). That was partly offset by a $30.3M fall in payables and accrued liabilities, which includes paying the class-action settlement booked in Q1. Running inventory down is a legitimate source of cash, but it can't continue indefinitely. At some point the cash has to come from the drug making a profit.
• The adjusted figure needs care. Amarin's non-GAAP net income excludes stock compensation ($2.1M), restructuring and, this year, $6.3M of litigation-related charges. It does not exclude last year's $25.0M upfront payment. That is why adjusted profit appears to collapse from $18.0M to $0.8M while GAAP results improve. Neither figure is the full story on its own.
• Small one-offs in other income. Other income of $1.1M came mostly from a COVID-era Employee Retention Credit, and the quarter also had a $0.2M tax benefit. Interest on the cash pile contributed $3.1M. Together these cover more than a third of the operating loss.
• No buybacks. A $50M repurchase program has been authorized since 2024, but "the Company has not commenced any share repurchases." The weighted ADS count was 20.8M, roughly flat, so the smaller per-ADS loss comes entirely from the smaller loss.

Legal overhang

Two litigation developments matter for the outlook:

• Patent case lost at the Supreme Court. On June 4, 2026, the US Supreme Court reversed an appeals court ruling and found that Amarin "failed to state a claim" that Hikma induced infringement of its cardiovascular-indication patents by selling generics. This ends Amarin's main legal route to damages from generic makers.
• Antitrust exposure remains. Dr. Reddy's, Hikma, Teva and Apotex are still suing Amarin in New Jersey, alleging that it restricted generic makers' access to the drug's active ingredient. In February 2026 the court denied Amarin's motions to dismiss the Teva and Apotex claims based on earlier settlements. The six purchaser class actions were settled in April 2026 for an undisclosed amount, which was expensed in Q1 and paid in Q2. The filing gives no estimate of possible losses from the remaining cases.

Takeaway: The restructuring did what it was meant to do: opex is down 38% and the company produced cash for a third straight quarter. But Amarin is now shipping more capsules for less money, and its product gross margin fell from 52% to 30% in a year (and from ~37% last quarter). Whether this business can reach break-even depends less on further cost cuts, which are mostly done, and more on whether that margin stops falling.

Outlook

Management's full-year 2026 outlook, from the July 29 release, includes no revenue or EPS figures. It expects US volumes to "remain consistent throughout FY 2026," VASCEPA's US market share to hold, continued growth in international partner demand, a lower opex base, positive cash flow, and cash about 10% higher at December 31, 2026 than the $302.6M at the end of 2025 (roughly $333M). The company is also working with Barclays as financial adviser to "explore additional potential pathways to further enhance shareholder value." That phrasing usually signals that a sale, merger or other strategic deal is under consideration, though nothing has been announced.

Our read: the cash target looks achievable, since cash was already $314.6M at mid-year with inventory still being drawn down. The harder question is profitability. Amarin needs about $27M of quarterly gross profit to cover its current opex. At a 30% product margin, gross profit is about $12M a quarter. Royalties are growing from a small base and won't close that gap on their own. In Q3 the first like-for-like European comparison arrives. The things to watch are whether US net price and product gross margin stabilize, and whether the Barclays review produces a deal.